The U.S. Food and Drug Administration (FDA) has cleared Pixyl's AI software for brain MRI analysis, Pixyl.Neuro.
The software boosts detection rates by up to 28%, according to the firm. It quantifies and compares MRI findings to identify abnormal atrophy earlier and support diagnosis, the company said.
Facilities in more than 12 countries across Europe, North America, and Africa are using Pixyl.Neuro, Pixyl said.
